About this trial
The inflatable penile prosthesis (IPP) is the gold standard for surgical management of erectile dysfunction (ED) and there is no consensus on the best postoperative pain management regimen. In the wake of the opioid epidemic, postoperative pain management is heavily scrutinized. The National Institute of Health estimated over 81,000 individuals died following overdose of any opioids in 2022 alone; of these, over 14,000 deaths were linked to prescription opioids. Thus, strategies to minimize postoperative pain should not only improve patient experience but also lessen the need to escalate to opioid usage.
Eligibility criteria
Qualifiers
Any patient undergoing primary three-piece inflatable penile prosthesis (IPP) placement at Lexington Medical Center
Disqualifiers
Patients undergoing revision and/or secondary IPP placement
Patients taking prescribed narcotic medications at the time of IPP surgery
Patients undergoing concomitant Peyronie's Disease surgery (modeling, plication, grafting) at the time of IPP surgery
Patients with liver and/or renal disease
Trial design
Treatments tested in this trial
- Exparel/bupivacaine mixture